Johnson & Johnson
NYSE: JNJ
$151.86
-$1.38 (-0.9%)
Closing Price on November 14, 2024
JNJ Articles
Johnson & Johnson officially enters the fight against COVID-19 as its single-shot vaccine was approved over the weekend. It plans to deliver 100 million single-shot vaccines during the first half of...
Published:
These five BofA Securities high-quality stock picks have good prospects for the rest of 2021 and should continue to be accompanied by dependable dividends. They may be an alternative for conservative...
Published:
24/7 Wall St. has put together a preview of those Dow companies scheduled to report their quarterly results this week, including Apple, Boeing, Microsoft and Verizon.
Published:
While positive earnings could continue to drive the major indexes higher in 2021, a very overbought and fully valued market could offer some painful January indigestion. These five stocks look like...
Published:
Rotating from overbought and crowded momentum stocks makes sense now. From a total return standpoint, dividend-paying large-cap pharmaceutical stocks may be one of the best ideas for 2021.
Published:
Some rather significant changes were made in the Berkshire Hathaway equity portfolio during the third quarter.
Published:
Health care is one sector that continues to draw a ton of fund manager interest, and with good reason. These five dividend-paying health care stocks are all favored by large-cap portfolio managers.
Published:
Johnson & Johnson released better than expected quarterly results before the markets opened on Tuesday, but it also announced a pause in its late-stage coronavirus vaccine trial.
Published:
A new earnings reporting season kicks off this week, with the big banks and a few other companies leading the way. These results will be an important barometer for what comes next.
Published:
President Trump and the First Lady have tested positive for COVID-19. That begs the question, now more than ever, of where we stand with a coronavirus vaccine.
Published:
These companies have a very good shot at crossing the finish line first with a COVID-19 vaccine. Even those that won't also have huge product lines and robust pipelines with future drug potential and...
Published:
The race for the COVID-19 vaccine is still very much on, and Johnson & Johnson just announced the launch of a Phase 3 trial.
Published:
The race for finding the COVID-19 vaccine is in full swing, and it has just seen one team move ahead of the others. Before getting into an actual prediction basis for knowing which vaccine (or...
Published:
America and the rest of the world is getting ready for a vaccine that will help protect public health against the COVID-19 pandemic. The societal impact of the coronavirus has changed many lives, and...
Published:
Three U.S. COVID-19 vaccine trials are now in Phase 3 studies. All three appear to have some serious benefits, but none are approved yet.
Published: